The FDA approves Abbott’s (NYSE:ABT) iOS-compatible Patient Controller app for use on smartphone devices, allowing patients with neurological conditions such as chronic pain or movement disorders to manage their therapy directly from their own smartphone.
The nod eliminates the need to carry a separate patient programmer device.
The company plans to integrate the app into its broader NeuroSphere Digital Care platform launched in May.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.